Sensus Healthcare (NASDAQ:SRTS) Upgraded to “Strong-Buy” at Roth Capital

Roth Capital upgraded shares of Sensus Healthcare (NASDAQ:SRTSFree Report) to a strong-buy rating in a research note issued to investors on Friday, Zacks.com reports. Roth Capital also issued estimates for Sensus Healthcare’s Q4 2025 earnings at $0.21 EPS, FY2026 earnings at $0.60 EPS and FY2027 earnings at $0.69 EPS.

A number of other research analysts also recently issued reports on the stock. HC Wainwright boosted their price target on shares of Sensus Healthcare from $8.00 to $10.00 and gave the stock a buy rating in a research report on Monday, May 13th. Maxim Group boosted their price target on shares of Sensus Healthcare from $7.00 to $10.00 and gave the stock a buy rating in a research report on Friday, May 10th.

Get Our Latest Stock Report on SRTS

Sensus Healthcare Price Performance

NASDAQ:SRTS opened at $6.17 on Friday. The firm’s 50 day simple moving average is $5.37 and its 200 day simple moving average is $4.18. Sensus Healthcare has a one year low of $1.79 and a one year high of $6.55. The company has a market cap of $101.14 million, a PE ratio of 21.28 and a beta of 1.00.

Sensus Healthcare (NASDAQ:SRTSGet Free Report) last posted its earnings results on Thursday, May 9th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.18. Sensus Healthcare had a net margin of 14.70% and a return on equity of 9.76%. The business had revenue of $10.66 million for the quarter, compared to the consensus estimate of $4.33 million. During the same period last year, the company earned ($0.12) EPS. Equities research analysts expect that Sensus Healthcare will post 0.29 EPS for the current year.

Insider Activity at Sensus Healthcare

In related news, Director John Heinrich sold 15,227 shares of the business’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $6.24, for a total transaction of $95,016.48. Following the transaction, the director now owns 59,940 shares in the company, valued at approximately $374,025.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.10% of the stock is owned by corporate insiders.

Institutional Trading of Sensus Healthcare

A number of hedge funds and other institutional investors have recently bought and sold shares of SRTS. Hillsdale Investment Management Inc. purchased a new stake in shares of Sensus Healthcare in the first quarter worth about $155,000. Creekmur Asset Management LLC bought a new position in Sensus Healthcare during the fourth quarter valued at approximately $83,000. Finally, Sachetta LLC bought a new position in Sensus Healthcare during the fourth quarter valued at approximately $247,000. Institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

(Get Free Report)

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Featured Articles

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.